Literature DB >> 23334813

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Michael N Dudley1, Paul G Ambrose, Sujata M Bhavnani, William A Craig, Mary Jane Ferraro, Ronald N Jones.   

Abstract

Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum β-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive evaluation, the Clinical and Laboratory Standards Institute recently adopted and published new breakpoints for these agents for use in clinical laboratories and provided updated recommendations for use of the ESBL screening test. This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334813     DOI: 10.1093/cid/cit017

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  57 in total

1.  Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Scott A Van Wart; Christopher M Rubino; Daniel K Reynolds; Alan Forrest; George L Drusano; Tatiana Khariton; H David Friedland; Todd A Riccobene; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.

Authors:  Emily L Heil; J Kristie Johnson
Journal:  J Clin Microbiol       Date:  2016-01-20       Impact factor: 5.948

3.  A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors:  Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  Treatment of extended-spectrum Beta-lactamase enterobacteriaceae with cefepime: the dose matters, too.

Authors:  Jerry Altshuler; Samuel L Aitken; David Guervil; Diana Esaian; John Papadopoulos; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2013-06-19       Impact factor: 9.079

5.  Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli.

Authors:  Nathaniel J Rhodes; Chad L Richardson; Ryan Heraty; Jiajun Liu; Michael Malczynski; Chao Qi; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 6.  Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.

Authors:  Romney M Humphries; April N Abbott; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

7.  Identification of Gram-Negative Bacteria and Genetic Resistance Determinants from Positive Blood Culture Broths by Use of the Verigene Gram-Negative Blood Culture Multiplex Microarray-Based Molecular Assay.

Authors:  Nathan A Ledeboer; Bert K Lopansri; Neelam Dhiman; Robert Cavagnolo; Karen C Carroll; Paul Granato; Richard Thomson; Susan M Butler-Wu; Heather Berger; Linoj Samuel; Preeti Pancholi; Lettie Swyers; Glen T Hansen; Nam K Tran; Christopher R Polage; Kenneth S Thomson; Nancy D Hanson; Richard Winegar; Blake W Buchan
Journal:  J Clin Microbiol       Date:  2015-05-20       Impact factor: 5.948

8.  Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms.

Authors:  Marc B Habash; Amber J Park; Emily C Vis; Robert J Harris; Cezar M Khursigara
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

9.  Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?

Authors:  Florian P Maurer; Patrice Courvalin; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2014-08-06       Impact factor: 5.948

10.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.